Evidence supporting the use of: Tauroursodeoxycholic Acid
For the health condition: Hepatitis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid derivative. Its primary clinical use has been in liver diseases, particularly in cholestatic conditions such as primary biliary cholangitis, due to its cytoprotective and anti-apoptotic effects on hepatocytes. There is some scientific basis for considering TUDCA in liver injury, including hepatitis, based on preclinical and limited clinical studies demonstrating that it can reduce hepatocyte apoptosis, improve bile flow, and potentially decrease liver inflammation and fibrosis. However, the direct evidence supporting TUDCA's use for viral hepatitis (such as hepatitis B or C) or autoimmune hepatitis in humans is limited. Most available data come from animal models or small pilot studies, which suggest that TUDCA might reduce liver enzyme levels and improve histological parameters of liver injury. Larger randomized controlled trials in hepatitis patients are lacking, so its use for hepatitis is not well-established in clinical guidelines. In summary, while TUDCA is scientifically validated for some cholestatic liver diseases, its application for hepatitis specifically is only weakly supported by early-stage scientific evidence. It is not a standard or first-line therapy for hepatitis, and more robust clinical trials are needed to establish its efficacy and safety in this context.

More about Tauroursodeoxycholic Acid
More about Hepatitis

Products containing Tauroursodeoxycholic Acid

We currently have no products on Vitabase that contain this ingredient.